August 23, 2010 Pharmalucence Mebrofenin amended labeling approved by FDA, post-reconstitution expiry extended to 18 hours.  Click here for details: PDF Click here to view posting on Daily Med web site: dailymed.nlm.nih.gov/dailymed/drugInfo.cfm August 19, 2010 Dear Healthcare Professional Letter; Pulmolite Lot 160034 Click here for details: PDF August 5, 2010 Pharmalucence Announces Drug Recall on DTPA Kit for the Preparation of Technetium Tc99m Pentetate Injection, Lots 2414, 2416                                         Click here for details: PDF July 22, 2010                     Pharmalucence Announces Drug Recall on Pulmolite® Kit for the Preparation of Technetium Tc99m Albumin Aggregated for Injection, Lot 160034 Click here for details: PDF June 3, 2010 Pharmalucence Announces Purchase of New Property in Billerica MA, to be Developed into New Corporate Headquarters and State-of-the-Art Drug Manufacturing Facility, beginning Summer 2010. COME SEE US IN 2010: ASNC: The 2010 American Society of Nuclear Cardiology Annual Meeting September 23-25, Philadelphia PA. Booth: 214 www.asnc.org/asnc2010 UPPI: The UPPI Annual Member Meeting September 29-October 3, Las Vegas NV.
	Pharmalucence, Inc. Is a leading provider of radiopharmaceuticals, including a broad range of Technetium Tc 99m cold kits. The company has recently received FDA approval to manufacture and market their Kit for the Preparation of Technetium Tc 99m Sestamibi Injection, a generic version of the industry's leading myocardial perfusion agent. Pharmalucence also provides contract and private label formulation development and manufacturing services of human injectables in either liquid or lyophilized form.   LEARN MORE ABOUT US